Profibrinolytic activities of chemically modified heparins with very low anticoagulant activities.
Many evidences indicate that heparin is an activator of fibrinolysis, but the most important side effect of heparin is bleeding which is a problem particularly in the high risk patient. Here we describe how chemical modifications, associated with separation techniques, can sharply reduce the anticoagulant activities of a heparin while its ability to stimulate fibrinolysis is retained.
Porta
R
R
Crinos Biological Laboratories, Como, Italy.
Pescador
R
R
Niada
R
R
Diamantini
G
G
Fedeli
G F
GF
Mantovani
M
M
Prino
G
G
D000818:Animals; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006493:Heparin / Q000302:isolation & purification / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D008970:Molecular Weight; D010084:Oxidation-Reduction; D011817:Rabbits; D051381:Rats; D012756:Sheep; D013552:Swine; D014574:Uronic Acids / Q000032:analysis
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014574:Uronic Acids; D006493:Heparin